Eli Lilly - 51 Year Stock Price History | LLY

Historical daily share price chart and data for Eli Lilly since 1972 adjusted for splits and dividends. The latest closing stock price for Eli Lilly as of November 28, 2023 is 591.60.
  • The all-time high Eli Lilly stock closing price was 617.99 on November 08, 2023.
  • The Eli Lilly 52-week high stock price is 629.97, which is 6.5% above the current share price.
  • The Eli Lilly 52-week low stock price is 302.14, which is 48.9% below the current share price.
  • The average Eli Lilly stock price for the last 52 weeks is 445.52.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Eli Lilly Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2023 451.3611 361.4341 617.9867 308.6038 591.6000 63.30%
2022 302.8070 265.4888 371.1090 230.2570 362.2759 34.24%
2021 218.1001 159.2870 272.6309 158.1513 269.8756 66.08%
2020 141.8503 124.7263 166.1493 112.8973 162.5016 31.06%
2019 109.1409 106.5918 124.9339 100.1652 123.9905 15.48%
2018 85.9924 76.6486 110.0806 67.1717 107.3712 40.45%
2017 73.5038 65.8050 79.5542 65.7874 76.4495 17.83%
2016 66.5383 71.1943 72.7937 58.1925 64.8788 -10.37%
2015 66.9114 58.6357 76.8228 57.6640 72.3884 25.37%
2014 50.8604 41.0970 60.9540 41.0970 57.7402 39.75%
2013 41.9099 38.6756 45.9833 38.2313 41.3157 7.24%
2012 33.3393 31.1829 41.6022 29.0758 38.5272 24.27%
2011 26.8044 24.7456 31.1456 24.1145 31.0039 25.15%
2010 24.2084 23.9606 26.5374 22.1902 24.7739 3.71%
2009 22.3526 25.6684 25.6684 17.6121 23.8870 -6.25%
2008 28.1271 31.8366 34.6416 18.9239 25.4786 -21.23%
2007 33.1183 30.7031 35.8649 29.7404 32.3455 5.65%
2006 31.9062 32.7196 33.9775 29.1896 30.6150 -5.16%
2005 30.9561 31.2100 33.9378 28.1761 32.2804 2.52%
2004 36.1304 38.6839 41.6066 27.8088 31.4874 -17.55%
2003 34.1472 35.2098 40.1228 28.7065 38.1897 13.14%
2002 34.1301 40.9207 42.2336 25.3229 33.7533 -17.56%
2001 41.2862 47.0488 47.0488 37.4560 40.9415 -14.44%
2000 40.2238 33.2399 55.4350 27.7489 47.8510 41.92%
1999 38.1174 43.0664 48.9236 31.0873 33.7165 -24.25%
1998 35.5691 34.1395 45.5101 28.9330 44.5086 29.08%
1997 25.8468 17.6382 34.6347 17.6382 34.4812 94.15%
1996 15.1926 13.1827 19.2803 11.7830 17.7598 32.64%
1995 9.4176 7.5058 13.4493 7.2331 13.3898 77.39%
1994 6.3556 6.5296 7.5483 5.2798 7.5483 15.60%
1993 5.5526 6.4381 6.6660 4.7451 6.5296 2.47%
1992 7.0588 8.6241 8.8517 6.1210 6.3720 -24.89%
1991 7.7884 7.2381 8.6241 6.8650 8.4839 16.41%
1990 7.0508 6.6524 8.8300 5.7821 7.2879 9.95%
1989 5.4457 4.0431 6.6282 4.0431 6.6282 64.17%
1988 3.8653 3.6594 4.2981 3.2579 4.0375 12.81%
1987 4.0135 3.3845 4.7689 2.8261 3.5791 5.75%
1986 3.1818 2.5014 3.7606 2.3190 3.3845 33.18%
1985 1.9331 1.4787 2.5413 1.4758 2.5413 68.95%
1984 1.3878 1.3561 1.5243 1.2307 1.5042 14.02%
1983 1.4279 1.3078 1.5585 1.2934 1.3192 0.66%
1982 1.2969 1.2706 1.4814 1.0598 1.3105 2.68%
1981 1.3293 1.4359 1.5555 1.0625 1.2763 -11.98%
1980 1.2146 1.3219 1.4500 1.0511 1.4500 6.71%
1979 1.2605 1.0940 1.4473 1.0853 1.3588 24.86%
1978 1.0256 0.8604 1.2250 0.8376 1.0883 26.06%
1977 0.8844 1.0739 1.0739 0.7494 0.8633 -20.46%
1976 1.1756 1.1651 1.3675 0.9942 1.0853 -7.75%
1975 1.4987 1.5298 1.8033 1.1596 1.1765 -24.09%
1974 1.5806 1.6724 1.8716 1.2820 1.5498 -8.11%
1973 1.8600 1.8033 2.0882 1.5981 1.6866 -7.06%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $567.306B $28.541B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $464.863B 42.98
Johnson & Johnson (JNJ) United States $360.875B 14.29
Merck (MRK) United States $260.194B 33.23
AbbVie (ABBV) United States $244.191B 11.60
Novartis AG (NVS) Switzerland $201.892B 14.03
AstraZeneca (AZN) United Kingdom $197.738B 17.72
Pfizer (PFE) United States $169.279B 10.45
Sanofi (SNY) $117.623B 10.64
Innoviva (INVA) United States $0.873B 7.87